Growing use of off-label neurological medicine for ache: research – company insurance
Ninety-nine percent of injured workers prescribed a common epilepsy drug had no documented diagnosis for any of the Food and Drug Administration-approved conditions, according to a study published Tuesday that linked the use of such drugs as alternatives to opioids in employee compensation.
The Workers & # 39; Compensation Research Institute, based in Cambridge, Massachusetts, looked at prescribing trends in 28 states and found that growing numbers of workers were using gabapentinoids – an umbrella classification for some neurological drugs – to treat pain from work-related injuries and to raise safety and abuse concerns received.
The study also found that gabapentinoids were more likely to be given off when drugs were prescribed to workers in some states. Missouri and New Jersey received gabapentinoids.
Gabapentinoids were almost always given for off-label use in the workers' compensation system, with between 96% and 99% of injured workers having no documented diagnosis for any of the FDA-approved conditions for such drugs.
While off-label gabapentinoid use is recommended on a limited study basis for selected disorders with neuropathic features, one-third of workers on gabapentinoid prescriptions in Employee Compensation had no diagnosis for neuropathic pain conditions or FDA-approved indications.
Gabapentinoid workers were often concomitantly given opioids, which increases the risk of respiratory depression, which can lead to overdose deaths. Almost half of workers on gabapentinoids in Iowa, Kansas, Louisiana, and Texas were given a prescription opioid at the same time, while the concurrent use rate in California and Nevada was 20% or less, according to WCRI.